Dr. Shandil, Director, FNDR, served AstraZeneca India, Bangalore, for 20 years in various scientific and managerial roles at Infection – innovative medicines group. Shandil was Head of DMPK & Animal Sciences and led multidisciplinary teams in biology, immunology and pharmacology. He played a central role in building microbiology, cell biology and Pharmacology based drug discovery platforms relevant to drug discovery in infectious diseases.
He was instrumental in building and managing state of the art bio-safety laboratories, a Vivarium, and validating animal models of tuberculosis, malaria and serious bacterial infections, PKPD and Pharmacology at AstraZeneca Bangalore. Shandil’s scientific leadership led to discovery and pre-clinical development of AZD 5847, an oxazolidinone class of compound that has recently completed Phase 2a/EBA clinical trial in TB patients. He led pharmacology of several TB and malaria lead optimization (LO) programs. His most recent & significant contribution includes discovery of Azaindoles, a yet-another clinical candidate for TB [Shirude. P et.al. Antimicrobial Agents and Chemotherapy, 2014, 58:5325-31]. He holds/shares patents for discovery of AZD 5847 and Azaindole class of compounds for the treatment of tuberculosis. He has ~30 publications in peer reviewed national and international journals, a dozen of them in very prestigious drug discovery journals like Antimicrobial Agents and Chemotherapy, Journal of Medicinal Chemistry, Tuberculosis and Science. Shandil is scientific consultant and advisor to biotech companies and Research Institutions and holds Adjunct faculty position at Transdisciplinary University, Bangalore.
LinkedIn | Email